All Type of News
“Domestic orphan drugs are welcomed,” proving their technology
Development of orphan disease treatments has been accelerated. As announcing to extend the health insurance benefit standards for orphan diseases, the Korean government is also expected to quicken the similar movement...
Will ‘Drug Pricing System Consultative Group’ make corrective measures for drug pricing system?
In order to improve the unreasonable drug pricing system, the ‘Drug Pricing System Consultative Group’ will have the first meeting today(3rd).
The group, formed by the Ministry of Health and Welfare(MOHW), will discu...
Dong-A ST wants competing product, Forsteo, to receive insurance benefit for its products, TeriboneDong-A ST has paid attention to the availability of the health insurance benefit of ‘Forsteo,’ an osteoporosis treatment which has not received the insurance benefit already for...
|
Zika virus fluctuates pharmaceutical- biopharmaceutical-related stocks
Through the news about the Zika virus spread, pharmaceutical- and biopharmaceutical-related stocks have been fluctuated. While there were stocks maintaining the ceiling price every day, there were stocks sharply dropp...
Will the Supect’s insurance benefit end the cruelty of domestic anticancer drugs?
A chronic myeloid leukemia(CML) treatment, ‘Supect(generic name: radotinib)’ has drawn attention if it would end the cruelty of domestic anticancer drugs as approved as a primary treatment with the health insurance be...
Shrunk NSAIDs market led by domestic drugs
The domestic osteoarthritis treatment market led by Pfizer Pharmaceuticals Korea’s ‘Celebrex’ has quickly been depressed.
The patent expiration of the leading product, Celebrex, and the increased prescriptions of NSA...
4-way competition in the Novel Oral Anticoagulant(NOAC) market
Competition is expected to be fiercer in the rapidly growing NOAC market.
As Daiichi Sankyo launched Lixiana with the insurance benefit on the 1st of February, the 3-way competition among Xarelto, Pradaxa and Eliquis...
Tightened CP deepens conflicts between companies and employees
Is it a painful change in the process of ethical management settlement or an unreasonable suffocation on employees?
As the atmosphere to tighten ethical management in the domestic pharmaceutical industry from the yea...
Will Sovaldi and Harvoni be registered for insurance benefit this June?
Due to the last year’s hepatitis C injection crisis at Dana Clinic, the health insurance benefit of Gilead Sciences’ Sovaldi Tab and Harvoni Tab have attracted attention of the industry.
According to the Ministry of ...
Massive original drugs’ patent walls will collapse for generic entry
Even in 2016, massive original drugs’ patents will collapse.
There are the total 11 original products expired in patent(based on substance patents) in 2016. Although none of them has an impact as huge as Baraclude wo...
